Drug
Octreotide clinical trials
Also written Sandostatin, SMS 201-995, SMS995 and MYCAPSSA™.
Includes 5 studies of Octreotide hydrochloride and 2 studies of Octreotide pamoate.
- studies test it
- 128
- open now
- 5
- in phase 3
- 32
- first study started
- 1995
Keep track of what changes. Save the Octreotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
124 studies that test it; most in 2005 (11); 1 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1996 | 2 |
| 1997 | 2 |
| 1998 | 2 |
| 1999 | 3 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 8 |
| 2003 | 7 |
| 2004 | 4 |
| 2005 | 11 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 19
- Phase 2
- 46
- Phase 3
- 32
- Phase 4
- 25
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 45 · Other 83
Novartis Pharmaceuticals (14) · Novartis (7) · Camurus AB (5) · Eastern Cooperative Oncology Group (4) · Endo Pharmaceuticals (4) · Columbia University (3) · Chiasma, Inc. (3) · Alliance for Clinical Trials in Oncology (3)
Often tested with
Tested in the same studies.
Midodrine (7) · Octreotide Depot Formulation CAM2029 (5) · Everolimus (4) · Glucose (3) · Terlipressin (3) · Pegvisomant (3) · Acetazolamide (2) · Atomoxetine (2)
Studies
Open first, then newest update. How each study uses Octreotide is read from its arms, and is right about nine times in ten.
Testing it · 128
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With AcromegalyNot yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07623824Written as Sandostatin LAR®
- Human Models of Selective Insulin Resistance: Pancreatic ClampNot yet recruitingPhase 1Columbia UniversityNCT06558422Written as Octreotide Acetate
- Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)Not yet recruitingPhase 4King Faisal Specialist Hospital & Research CenterNCT06974344Written as Octreotide (drug)
- Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.RecruitingPhase 2Clinica Universidad de Navarra, Universidad de NavarraNCT06085976Written as Octreotide
- Role of Octreotide in Non Variceal BleedingRecruitingPhase 2/3National Hepatology & Tropical Medicine Research InstituteNCT06062719Written as PPI plus octreotide
- Treatment of Orthostatic IntoleranceActive, not recruitingPhase 1/2Satish R. RajNCT00262470Written as Octreotide
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular EdemaWithdrawnPhase 1University of Alabama at BirminghamNCT06881888Written as Octreotide (drug)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04076462Written as CAM2029 (octreotide subcutaneous depot)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETActive, not recruitingPhase 3Camurus ABNCT05050942Written as CAM2029
- RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00113360Written as Octreotide Depot
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDActive, not recruitingPhase 2/3Camurus ABNCT05281328Written as CAM2029
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT03879694Written as Octreotide Acetate
- Pancreatic Clamp in NAFLDCompletedPhase 1Columbia UniversityNCT05724134Written as Octreotide Acetate
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04125836Written as CAM2029 (octreotide subcutaneous depot)
- Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal VaricesTerminatedPhase 4Medical University of South CarolinaNCT03624517Written as Octreotide
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedPhase 1Debiopharm International SANCT05364944Written as Sandostatin LAR
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus LanreotideCompletedPhase 4Memorial Sloan Kettering Cancer CenterNCT03289741Written as Octreotide
- Treatment of Idiopathic Pulmonary Fibrosis with Long Acting OctreotideCompletedPhase 1/2Institut National de la Santé Et de la Recherche Médicale, FranceNCT00463983Written as octreotide
- Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric CancerCompletedPhase 2Fredrik KlevebroNCT04871204Written as Octreotide Injection
- Effects of Sandostatin LAR® in AcromegalyCompletedPhase 4Columbia UniversityNCT01424241Written as Sandostatin LAR
See all 128 studies that test Octreotide →
Given in every arm · 25 — Octreotide is usual care beside what is tested
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETRecruitingPhase 3Novartis PharmaceuticalsNCT06784752Written as Octreotide LAR
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00569127Written as Octreotide Acetate
- Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine CarcinomasCompletedPhase 2/3Grupo Espanol de Tumores NeuroendocrinosNCT01744249Written as Sandostatin LAR
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingPhase 3Advanced Accelerator ApplicationsNCT03972488Written as 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)
- Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasTerminatedPhase 2National Cancer Institute (NCI)NCT06865677Written as Octreotide
- Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomyCompletedPhase 3University of LiverpoolNCT02457156Written as Octreotide
- Dexamethasone/Pancreatic Clamp P&FWithdrawnPhase 1Columbia UniversityNCT06126354Written as Octreotide Acetate
- Acromegaly Combination Treatment StudyTerminatedNot applicableCedars-Sinai Medical CenterNCT01538966Written as Octreotide LAR
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01229943Written as Octreotide Acetate
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedPhase 3Advanced Accelerator ApplicationsNCT01578239Written as Octreotide LAR
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.CompletedPhase 4Novartis PharmaceuticalsNCT01789281Written as Sandostatin LAR Depot
- A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid TumorsWithdrawnPhase 1Massachusetts General HospitalNCT03057509Written as LAR Octreotide
- Effects of Glucagon Administration on Energy ExpenditureCompletedPhase 1AdventHealth Translational Research InstituteNCT02237053Written as Octreotide
- The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated AcromegalicsCompletedPhase 2Aspireo Pharmaceuticals LimitedNCT02217800Written as octreotide
- RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal BleedingCompletedNot applicableTheodor Bilharz Research InstituteNCT03061604Written as Octreotide
- Study of Intranasal Octreotide (DP1038) in Healthy Adult VolunteersCompletedPhase 1Dauntless PharmaceuticalsNCT03031535Written as Intranasal octreotide acetate
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedPhase 4Novartis PharmaceuticalsNCT01278342Written as Sandostatin LAR
- Surgical Debulking of Pituitary AdenomasCompletedPhase 4NYU Langone HealthNCT01371643Written as Octreotide LAR
- Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersCompletedPhase 2SCRI Development Innovations, LLCNCT01121939Written as Sandostatin LAR® Depot
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT02012166Written as Sandostatine®
Showing 20 of 25.
As the comparator · 14 — what is tested is compared with Octreotide
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Octreotide
- A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)CompletedPhase 1Triastek (Shanghai) LimitedNCT07663318Written as Mycapssa
- A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyCompletedPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07814651Written as Sandostatin LAR
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal SyndromeCompletedNot applicableLahore General HospitalNCT07460908Written as Octreotide (drug)
- Prevention of Postoperative Pancreatic Fistula by SomatostatinCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT03000946Written as Octreotide
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsActive, not recruitingPhase 3Sinotau Pharmaceutical GroupNCT05459844Written as Octreotide LAR
- Angiotensin 2 for Hepatorenal SyndromeWithdrawnPhase 2University of California, Los AngelesNCT04048707Written as Octreotide
- Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®SuspendedPhase 1Azidus BrasilNCT01086982Written as Sandostatin LAR ® (octreotide acetate LAR) 30 MG
- Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)Status unknownPhase 4Nanfang Hospital, Southern Medical UniversityNCT04028323Written as Octreotide
- A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersTerminatedPhase 1Ono Pharmaceutical Co. LtdNCT03571594Written as Octreotide
- Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedPhase 3Novartis PharmaceuticalsNCT00600886Written as Octreotide
- Phase II Study With ITF2984 in Acromegalic PatientsCompletedPhase 2ItalfarmacoNCT02111044Written as Octreotide
- Hemodynamic Effects of Terlipressin and High Dose OctreotideCompletedPhase 4Shanghai Zhongshan HospitalNCT02119884Written as Octreotide
- ITF2984 Repeated Doses Study in Healthy VolunteersCompletedPhase 1ItalfarmacoNCT01871844Written as octreotide 50 mcg tid
Codes
What other systems call Octreotide · ClinicalTrials.gg INT008456
- MeSH (NLM) D015282OctreotideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RWM8CCW8GPOCTREOTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 7617Confirmed FDA, Wikidata
- Wikidata Q419935octreotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C711OctreotideConfirmed FDA, Wikidata
- DrugBank DB00104One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015282 | Octreotide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RWM8CCW8GP | OCTREOTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7617 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419935 | octreotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C711 | Octreotide | Confirmed FDA, Wikidata |
| DrugBank | DB00104 | — | One source Wikidata |
Also registered as octreotide acetate (UNII 75R0U2568I · RxNorm 221130).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.